Capricor Therapeutics Inc Share Price Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 237M 205M 191M 176M 330M 22.54B 335M 2.24B 881M 11.3B 889M 870M 37.35B | P/E 2026 * |
-2.89x | P/E 2027 * | -2.93x |
|---|---|---|---|---|---|
| Enterprise Value | 237M 205M 191M 176M 330M 22.54B 335M 2.24B 881M 11.3B 889M 870M 37.35B | EV / Sales 2026 * |
3.66x | EV / Sales 2027 * | 4.9x |
| Free-Float |
90.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 19/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 31/12/2017 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 31/10/2013 |
David Musket
BRD | Director/Board Member | 68 | 19/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 19/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 237M | |
| +8.49% | +20.55% | +70.77% | +110.32% | 68.12B | |
| +1.25% | +2.44% | +34.27% | +70.43% | 55.18B | |
| -1.09% | +32.96% | +19.67% | +494.56% | 28.63B | |
| +10.83% | +18.38% | +56.20% | +6.03% | 23.99B | |
| +2.72% | +3.41% | -16.11% | -7.96% | 23.53B | |
| +6.50% | +7.56% | +44.65% | -21.73% | 18.45B | |
| +6.20% | +11.51% | +33.87% | +693.38% | 16.44B | |
| -3.88% | +16.98% | +199.30% | +359.77% | 15.83B | |
| +3.58% | +1.96% | +43.35% | +163.76% | 13.4B | |
| Average | +4.46% | +11.68% | +54.00% | +207.62% | 29.28B | |
| Weighted average by Cap. | +4.36% | +13.10% | +50.69% | +168.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 64.76M 56.02M 52.31M 47.99M 90.26M 6.16B 91.69M 614M 241M 3.09B 243M 238M 10.21B | 48.38M 41.85M 39.08M 35.85M 67.43M 4.6B 68.5M 458M 180M 2.31B 182M 178M 7.63B |
| Net income | -82.36M -71.25M -66.53M -61.03M -115M -7.84B -117M -781M -306M -3.93B -309M -303M -12.99B | -83.73M -72.42M -67.63M -62.04M -117M -7.97B -119M -794M -311M -3.99B -314M -308M -13.2B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
